CXCR3 and neoplasm: In contrast, in the OV2944-HM-1 model, which was insensitive to anti-PD-L1 mAb treatment, expression of CXCR3 ligands in the tumor was lower than that in the FM3A model and we confirmed that anti-PD-L1 mAb treatment increased the number of CD69+CD8α+ T cells in lymph nodes but not in tumors (Fig. 5F).